76 A new review has spotlighted the potential of nanozymes, which are tiny enzyme mimicking nanomaterials, in transforming the diagnosis and treatment of glioblastoma, one of the most aggressive forms of brain cancer. Despite decades of medical advances, glioblastoma remains exceptionally difficult to treat because of its invasive nature and the protective barrier that surrounds the brain. Published in the Journal of Nanotheranostics, the study outlines how nanozymes, which combine the structural properties of nanomaterials with the catalytic functions of natural enzymes, could change the future of cancer care. These nanostructures are uniquely capable of entering the blood brain tumour barrier, a weakened yet still protective version of the brain’s natural defence system, allowing for more accurate drug delivery with fewer side effects. Traditional treatments like chemotherapy often struggle to reach brain tumours in a focused way, which can lead to damage to healthy tissue. According to the study, nanozymes, because of their smart design and small size, can overcome these obstacles and deliver treatments directly to the site of the tumour. This would make existing treatments more effective while protecting surrounding brain tissue. Glioblastoma accounts for most malignant brain tumours and continues to have a poor outlook for patients. Current therapies, including surgery, radiation, and chemotherapy, offer only limited success. A key challenge is that most traditional drugs cannot pass through the brain’s natural protective filter. This selective membrane is designed to keep harmful substances out of the brain, but it also blocks treatments that could help. Nanozymes provide a way around this by using their adaptable surfaces and enzyme like activity to move past these barriers more effectively. The review describes how nanozymes can serve multiple purposes. They can be designed to carry drugs, detect tumour signals, and even support immune system responses. This makes them ideal for a new approach to brain cancer treatment where diagnosis and therapy are combined into one tool, a concept known as theranostics. Another benefit of nanozymes is their durability. Unlike natural enzymes, which can break down inside the human body, nanozymes are more stable and can keep working in conditions that usually limit the success of standard treatments. They are also easier to produce in large quantities, which is important if they are to be used widely in healthcare. Although most nanozyme technologies are still in the early stages of research, some are already moving towards clinical testing. The review notes that more than five hundred different nanozymes have been created around the world, with many showing positive results in early trials for brain cancer. There are still hurdles to clear. Researchers must ensure nanozymes are safe over the long term and behave in predictable ways inside the body. However, the study concludes that with continued work across different scientific disciplines, nanozymes have the potential to become a powerful tool in treating brain cancer.